Alnylam 8-K Signals Upcoming Financial Disclosure
Ticker: ALNY · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1178670
Complexity: simple
Sentiment: neutral
Topics: financial-update, results-of-operations, exhibits
TL;DR
**Alnylam filed an 8-K, likely signaling a financial update is coming.**
AI Summary
Alnylam Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 7, 2024, related to "Results of Operations and Financial Condition" and "Financial Statements and Exhibits." This filing indicates that the company is likely providing an update on its financial performance or releasing new financial statements. For investors, this matters because it could signal upcoming earnings announcements or other significant financial disclosures that will impact the stock's valuation and future prospects.
Why It Matters
This filing suggests Alnylam is preparing to release important financial information, which could significantly influence investor perception and the stock price.
Risk Assessment
Risk Level: medium — The filing itself doesn't contain specific financial details, so the risk is medium as the actual impact depends on the content of the upcoming disclosure.
Analyst Insight
A smart investor would monitor Alnylam's news releases closely for the specific financial details that this 8-K is foreshadowing, as these will provide concrete data for valuation adjustments.
Key Players & Entities
- Alnylam Pharmaceuticals, Inc. (company) — the filer of the 8-K
- January 8, 2024 (date) — the filing date of the 8-K
- January 7, 2024 (date) — the date of the earliest event reported in the 8-K
- 001-36407 (other) — Commission File Number for Alnylam Pharmaceuticals, Inc.
- ALNY (other) — Trading Symbol for Alnylam Pharmaceuticals, Inc.
Forward-Looking Statements
- Alnylam Pharmaceuticals, Inc. will release its Q4 2023 or full-year 2023 earnings report soon. (Alnylam Pharmaceuticals, Inc.) — medium confidence, target: 2024-02-15
- The upcoming financial disclosure will include specific revenue figures for its key products. (Alnylam Pharmaceuticals, Inc.) — medium confidence, target: 2024-02-15
FAQ
What is the primary purpose of this 8-K filing by Alnylam Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing, as indicated by the 'ITEM INFORMATION', is to report on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' for an event that occurred on January 7, 2024.
When was this 8-K filed and what was the date of the earliest event reported?
This 8-K was filed on January 8, 2024, and the earliest event reported occurred on January 7, 2024.
What is Alnylam Pharmaceuticals, Inc.'s trading symbol and on which exchange is its common stock registered?
Alnylam Pharmaceuticals, Inc.'s trading symbol is ALNY, and its common stock, with a $0.01 par value per share, is registered on The Nasdaq Stock Market LLC.
What is the business address and phone number of Alnylam Pharmaceuticals, Inc.?
The business address for Alnylam Pharmaceuticals, Inc. is 675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts, 02142, and their telephone number is (617) 551-8200.
Under which SEC Act is this 8-K filed?
This 8-K is filed under the 1934 Act, pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 595 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-01-08 07:00:54
Key Financial Figures
- $0.01 — nge on Which Registered Common Stock, $0.01 par value per share ALNY The Nasdaq
- $346 million — l net product revenues of approximately $346 million and $1,241 million, respectively, for O
- $1,241 m — enues of approximately $346 million and $1,241 million, respectively, for ONPATTRO (pati
- $2.4 billion — marketable securities of approximately $2.4 billion. The preliminary selected financial r
Filing Documents
- d34101d8k.htm (8-K) — 25KB
- d34101dex991.htm (EX-99.1) — 20KB
- g34101g0107004255132.jpg (GRAPHIC) — 3KB
- 0001193125-24-003854.txt ( ) — 176KB
- alny-20240107.xsd (EX-101.SCH) — 3KB
- alny-20240107_lab.xml (EX-101.LAB) — 18KB
- alny-20240107_pre.xml (EX-101.PRE) — 11KB
- d34101d8k_htm.xml (XML) — 3KB
02
Item 2.02. Results of Operations and Financial Condition On January 7, 2024, Alnylam Pharmaceuticals, Inc. (the "Company") announced its preliminary fourth quarter and full year 2023 global net product revenues of approximately $346 million and $1,241 million, respectively, for ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran) and OXLUMO (lumasiran). The Company also provided its cash balance for the year ended December 31, 2023, stating that at December 31, 2023, it had preliminary cash, cash equivalents and marketable securities of approximately $2.4 billion. The preliminary selected financial results reported by the Company are unaudited, subject to adjustment, and provided as an approximation in advance of the Company's announcement of complete financial results in February 2024. The information in this Item 2.02 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: 99.1 Press Release dated January 7, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALNYLAM PHARMACEUTICALS, INC. Date: January 8, 2024 By: /s/ Jeffrey V. Poulton Jeffrey V. Poulton Executive Vice President, Chief Financial Officer